Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1995 1
2003 2
2005 2
2007 1
2009 1
2010 1
2011 1
2012 1
2013 1
2015 2
2018 1
2019 1
2020 1
2021 3
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK; CLEAR Trial Investigators. Motzer R, et al. N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13. N Engl J Med. 2021. PMID: 33616314 Clinical Trial.
JNO Literature Commentary.
[No authors listed] [No authors listed] J Neuroophthalmol. 2021 Jun 1;41(2):272-277. doi: 10.1097/WNO.0000000000001267. J Neuroophthalmol. 2021. PMID: 33999891
June 2021' In this issue of JNO, Drs. M. Tariq Bhatti and Mark L. Moster discuss the following 6 articles: Vynckier J, Demeestere J, Lambert J. ...Epub ahead of print. PMID: 33525898.Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli …
June 2021' In this issue of JNO, Drs. M. Tariq Bhatti and Mark L. Moster discuss the following 6 articles: Vynckier J, Demeest …
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Géczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ; METEOR Investigators. Choueiri TK, et al. N Engl J Med. 2015 Nov 5;373(19):1814-23. doi: 10.1056/NEJMoa1510016. Epub 2015 Sep 25. N Engl J Med. 2015. PMID: 26406150 Free PMC article. Clinical Trial.
Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema.
Jhaveri CD, Glassman AR, Ferris FL 3rd, Liu D, Maguire MG, Allen JB, Baker CW, Browning D, Cunningham MA, Friedman SM, Jampol LM, Marcus DM, Martin DF, Preston CM, Stockdale CR, Sun JK; DRCR Retina Network. Jhaveri CD, et al. N Engl J Med. 2022 Aug 25;387(8):692-703. doi: 10.1056/NEJMoa2204225. Epub 2022 Jul 14. N Engl J Med. 2022. PMID: 35833805 Free PMC article. Clinical Trial.
Consensus Statement: Toward Opioid-Free Arthroplasty: A Leadership Forum.
Waldman S, Cornell CN, Shapiro LA, Albert TJ, Schairer W, Rodriguez-Merchan EC, Soffin EM, Wu CL, Barnes M, Rich A, Avery J, Rieder TN. Waldman S, et al. HSS J. 2019 Feb;15(1):4-7. doi: 10.1007/s11420-018-09664-w. Epub 2019 Feb 1. HSS J. 2019. PMID: 30863224 Free PMC article. No abstract available.
The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma.
Palacio S, Hosein PJ, Reis I, Akunyili II, Ernani V, Pollack T, Macintyre J, Restrepo MH, Merchan JR, Rocha Lima CM. Palacio S, et al. J Gastrointest Oncol. 2018 Feb;9(1):135-139. doi: 10.21037/jgo.2017.10.12. J Gastrointest Oncol. 2018. PMID: 29564179 Free PMC article.
Demographic and survival data were extracted from the registry. Patients received nab-paclitaxel 125 mg/m(2) and gemcitabine 1,000 mg/m(2) and on days 1, 8 and 15 of a 28-day cycle with subsequent dose modifications based on tolerance. ...
Demographic and survival data were extracted from the registry. Patients received nab-paclitaxel 125 mg/m(2) and gemcitabine 1,000 mg …
Phenotypical, Clinical, and Molecular Aspects of Adults and Children With Homozygous Familial Hypercholesterolemia in Iberoamerica.
Alves AC, Alonso R, Diaz-Diaz JL, Medeiros AM, Jannes CE, Merchan A, Vasques-Cardenas NA, Cuevas A, Chacra AP, Krieger JE, Arroyo R, Arrieta F, Schreier L, Corral P, Bañares VG, Araujo MB, Bustos P, Asenjo S, Stoll M, Dell'Oca N, Reyes M, Ressia A, Campo R, Magaña-Torres MT, Metha R, Aguilar-Salinas CA, Ceballos-Macias JJ, Morales ÁJR, Mata P, Bourbon M, Santos RD. Alves AC, et al. Arterioscler Thromb Vasc Biol. 2020 Oct;40(10):2508-2515. doi: 10.1161/ATVBAHA.120.313722. Epub 2020 Aug 6. Arterioscler Thromb Vasc Biol. 2020. PMID: 32757650 Free article.
Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer.
Merchan JR, Ferrell A, Macintyre J, Ciombor KK, Levi J, Ribeiro A, Sleeman D, Flores A, Lopes G, Rocha-Lima CM. Merchan JR, et al. Am J Clin Oncol. 2012 Oct;35(5):446-50. doi: 10.1097/COC.0b013e31821862fb. Am J Clin Oncol. 2012. PMID: 21552097 Clinical Trial.
Eligible, chemotherapy-naive PC patients were treated with gemcitabine (1000 mg/m(2) over 100 min) on day 1, oxaliplatin (100 mg/m(2)) on day 2, every 2 weeks, and weekly cetuximab, (loading dose of 400 mg/m(2) on cycle 1 day 1 and 250 mg/m(2) thereaft …
Eligible, chemotherapy-naive PC patients were treated with gemcitabine (1000 mg/m(2) over 100 min) on day 1, oxaliplatin (100 mg/m …
A new algorithm for predicting triplet-triplet energy-transfer activated complex coordinate in terms of accurate potential-energy surfaces.
Frutos LM, Castaño O. Frutos LM, et al. J Chem Phys. 2005 Sep 8;123(10):104108. doi: 10.1063/1.1993592. J Chem Phys. 2005. PMID: 16178590
This algorithm makes use of the complete potential-energy surfaces (singlet and triplet states), and contrasts with the first-order approximation already published [L. M. Frutos, O. Castano, J. L. Andres, M. Merchan, and A. U. Acuna, J. ...
This algorithm makes use of the complete potential-energy surfaces (singlet and triplet states), and contrasts with the first-order approxim …
22 results